Guido Lancman, MD, on the Use of IVIg in Patients with Multiple Myeloma Receiving Daratumumab

Research presented at the 2020 American Society of Hematology Annual Meeting & Exposition sought to evaluate the effect of intravenous immunoglobulin (IVIg) on infections in patients with multiple myeloma receiving daratumumab (Darzalex).

Infection risk in multiple myeloma is the result of a complex interplay of disease, treatment, and age-related risks and co-morbidities.

In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, discussed the results of the study.

Transcription:

What we found was that in the periods [where] patients were getting IVIg, the rate of infections overall actually decreased by 39% from 1.96 [infections] per patient year to 1.21 per patient year. And when we looked at grade 3 or higher infections, we actually found an even greater reduction of 72% from 0.71 to 0.2 infections per patient year.